市場調査レポート

商品コード

1403382

神経内分泌腫瘍治療市場の世界市場予測（～2030年）：治療法、病状、投与経路、部位分析、エンドユーザー、地域別の分析

Neuroendocrine Tumor Treatment Market Forecasts to 2030 - Global Analysis By Service, Animal Model, Model Type, End User and By Geography

出版日: 2024年01月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 597,849円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 756,315円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 914,781円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,080,450円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の神経内分泌腫瘍治療の市場規模は、2023年に25億8,720万米ドルを占め、予測期間中にCAGR15.7％で成長し、2030年には71億8,070万米ドルに達すると予測されています。

神経内分泌腫瘍治療は、神経内分泌細胞から発生する多様な希少新生物群である神経内分泌腫瘍（NETs）の管理を目的とした一連の医療介入を含みます。これらの腫瘍は多くの臓器に発生する可能性がありますが、膵臓および消化器系に発生することが最も多いです。

2021年11月に更新されたNational Center for Advancing Translational Sciences-Genetic and Rare Diseases Information Centerのデータによると、米国にはカルチノイド腫瘍に罹患している人が約3,000～30,000人おり、通常は消化管または肺に発生します。

神経内分泌腫瘍治療の拡大

患者数の増加により、製薬企業やバイオテクノロジー企業は、早期診断による患者の転帰の改善や適切な介入のための研究開発に資金を費やすようになりました。診断技術の向上、認知度の向上、ライフスタイルの変化、分子プロファイリングによる精密医療など、いくつかの要因が個別化治療戦略を可能にし、この市場規模を押し上げています。

高額な治療費

患者は、処方薬、医療処置、入院、経過観察に費用がかかるため、特に経済的に余裕がない場合や保険が十分でない場合、高額な治療を受けることが困難となる可能性があります。神経内分泌腫瘍の治療には高額な費用がかかるため、医療システムが十分な資金を割くことが困難となり、このような必要不可欠な治療へのアクセスが制限され、手ごろな価格で受けられなくなる可能性があります。さらに、保険適用の格差や高額な自己負担は、患者が最適な治療を受けることをさらに妨げます。

研究開発の進歩

分子プロファイリングはNET研究の重要な側面として浮上し、これらの腫瘍に関連する特定のバイオマーカーや遺伝子変異の同定を可能にしました。これらの発見は、ソマトスタチン類似体、mTOR阻害剤、ペプチド受容体放射性核種療法（PRRT）などの革新的な治療法の導入につながっています。さらに、現在進行中の科学的発見は、分子メカニズムや遺伝的要因のより深い理解に貢献し、最終的には患者の予後を改善し、利用可能な治療法の幅を広げることで、市場の成長を促進しています。

認識不足

神経内分泌腫瘍（NET）は比較的まれで、さまざまな症状を呈するため、発見が困難です。これらの腫瘍は多くの医療関係者にあまり知られていないため、診断の遅れや誤診を引き起こす可能性があります。さらに、NETに関する知識が不足しているため、症状を誤って解釈し、医療機関を受診するのが遅れます。このような認識不足は、より広範な医学界にも及び、NET症例の管理が最適でなくなる可能性があります。

COVID-19の影響

神経内分泌腫瘍治療市場はCOVID-19の大流行により悪影響を受けました。医療施設の閉鎖と収容能力の制限の結果、神経内分泌腫瘍の発見と治療が遅れ、患者の転帰に影響を与えました。革新的な医薬品の臨床試験は制限され、パンデミックへの対応に資源と注意が振り向けられたため、医療サービスの利用は伸び悩みました。さらに、免疫抑制に対する懸念や医療システムの財政的制約も、治療の開始や維持に対する意欲に影響を及ぼし、市場規模を徐々に押し下げる要因となりました。

予測期間中、化学療法セグメントが最大となる見込み

化学療法セグメントが最大のシェアを占めると推定されます。化学療法は通常、手術や他の治療法の効果が低い場合に検討され、多くの場合、NETの進行期や転移期に行われます。化学療法は症状を抑え、腫瘍の成長を抑え、患者のQOLを高めるのに役立ちますが、治療が必ずしも治癒するとは限りません。さらに、神経内分泌腫瘍患者の副作用を軽減し、治療成績を改善するために、標的を絞った個別化化学療法レジメンが研究されており、このセグメントの拡大を後押ししています。

予測期間中、膵神経内分泌腫瘍セグメントのCAGRが最も高くなると予測される

膵神経内分泌腫瘍セグメントは、予測期間中にCAGRが最も高くなると予測されています。これらの腫瘍は膵臓の内分泌細胞から発生し、その明確な特徴から専門的な治療を考慮する必要があります。pNETの治療アプローチには、腫瘍の悪性度、病期、機能性などの要因を考慮した集学的戦略が含まれます。さらに、進行性または転移性pNETに対する治療オプションには、ホルモンに関連した症状をコントロールし、腫瘍の成長を促進する経路を阻害するソマトスタチン類似体があり、これがこのセグメントの成長を牽引しています。

最大のシェアを占める地域

PET-CTスキャンや分子プロファイリングなどの高度な診断ツールが神経内分泌腫瘍の早期発見と特徴付けを強化したため、推定期間中、アジア太平洋地域が最大の市場シェアを占める見通しです。標的療法や免疫療法が脚光を浴び、より効果的で個別化された治療オプションが提供されています。さらに、医療利害関係者、政府機関、製薬企業間の協力的な取り組みが、こうした格差に対処し、神経内分泌腫瘍治療全体を強化する上で極めて重要であり、これがこの地域の成長を牽引しています。

CAGRが最も高い地域：

北米は、患者の治療へのアクセスに大きく影響する政府の医療政策と保険適用により、予測期間中に最も高いCAGRを示すと予想されます。Eli Lilly & Company、Novartis AG、Hutchison MediPharma Limited、Pfizer Inc.などの主な企業は、この地域の厳しい規制や医療・研究に対する大規模な公的・民間投資により、有利な環境で開発を進めています。FDA（米国食品医薬品局）のような規制機関は、医薬品や治療器具の承認において中心的な役割を果たし、安全性と有効性を確保しており、これがこの地域の拡大を後押ししています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第11章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

Novartis AG
Exelixis, Inc.
Boehringer Ingelheim International GmbH
Tarveda Therapeutics
Dauntless Pharmaceuticals
Hutchison MediPharma Limited
AVEO Oncology
Pfizer Inc.
Ipsen Pharma
Progenics Pharmaceuticals, Inc.
Eli Lilly & Company
Lantheus Holdings, Inc.
Jubilant Life Sciences Ltd.

図表

List of Tables

Table 1 Global Neuroendocrine Tumor Treatment Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 3 Global Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 4 Global Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 5 Global Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 6 Global Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 7 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 8 Global Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 9 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 10 Global Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 11 Global Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 12 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 13 Global Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 14 Global Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 15 Global Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 16 Global Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 17 Global Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 18 Global Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 19 Global Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 20 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 21 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 22 Global Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 23 Global Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 24 Global Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 25 Global Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 26 Global Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
Table 27 North America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 28 North America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 29 North America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 30 North America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 31 North America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 32 North America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 33 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 34 North America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 35 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 36 North America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 37 North America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 38 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 39 North America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 40 North America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 41 North America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 42 North America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 43 North America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 44 North America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 45 North America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 46 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 47 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 48 North America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 49 North America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 50 North America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 51 North America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 52 North America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
Table 53 Europe Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 54 Europe Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 55 Europe Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 56 Europe Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 57 Europe Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 58 Europe Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 59 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 60 Europe Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 61 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 62 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 63 Europe Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 64 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 65 Europe Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 66 Europe Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 67 Europe Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 68 Europe Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 69 Europe Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 70 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 71 Europe Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 72 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 73 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 74 Europe Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 75 Europe Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 76 Europe Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 77 Europe Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 78 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
Table 79 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 80 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 81 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 82 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 83 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 84 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 85 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 86 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 87 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 88 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 89 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 90 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 91 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 92 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 93 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 94 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 95 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 96 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 97 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 98 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 99 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 100 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 101 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 102 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 103 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 104 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
Table 105 South America Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 106 South America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 107 South America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 108 South America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 109 South America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 110 South America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 111 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 112 South America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 113 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 114 South America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 115 South America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 116 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 117 South America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 118 South America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 119 South America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 120 South America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 121 South America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 122 South America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 123 South America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 124 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 125 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 126 South America Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 127 South America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 128 South America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 129 South America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 130 South America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
Table 131 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 132 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2021-2030) ($MN)
Table 133 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
Table 134 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
Table 135 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2021-2030) ($MN)
Table 136 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
Table 137 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2021-2030) ($MN)
Table 138 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
Table 139 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2021-2030) ($MN)
Table 140 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2021-2030) ($MN)
Table 141 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2021-2030) ($MN)
Table 142 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
Table 143 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 144 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
Table 145 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 146 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2021-2030) ($MN)
Table 147 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Colon (2021-2030) ($MN)
Table 148 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2021-2030) ($MN)
Table 149 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2021-2030) ($MN)
Table 150 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2021-2030) ($MN)
Table 151 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2021-2030) ($MN)
Table 152 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By End User (2021-2030) ($MN)
Table 153 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 154 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 155 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 156 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24607

According to Stratistics MRC, the Global Neuroendocrine Tumor Treatment Market is accounted for $2,587.2 million in 2023 and is expected to reach $7,180.7 million by 2030 growing at a CAGR of 15.7% during the forecast period. Neuroendocrine tumor treatment encompasses a range of medical interventions aimed at managing neuroendocrine tumors (NETs), a diverse group of rare neoplasms that arise from neuroendocrine cells. These tumors can develop in a number of organs, although they most frequently affect the pancreas and digestive system.

According to the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs.

Market Dynamics:

Driver:

Expansion of neuroendocrine tumor treatments

The growing number of patients has encouraged pharmaceutical and biotechnology businesses to spend money on research and development for better patient outcomes and appropriate interventions resulting from early diagnosis. Several factors including improved diagnostic techniques, greater awareness, and changes in lifestyle, precision medicine, guided by molecular profiling, allows for personalized therapeutic strategies, which are driving this market size.

Restraint:

High treatment costs

Patients may find it difficult to receive high-cost treatments, especially if they have limited financial resources or insufficient insurance, due to the expense of prescription drugs, medical procedures, hospital stays, and follow-up care. The high expense of treating neuroendocrine tumors may make it difficult for healthcare systems to devote enough funding, which could restrict the accessibility and affordability of these essential treatments. Furthermore, insurance coverage gaps and high out-of-pocket expenses further impede patient access to optimal treatment.

Opportunity:

Advancements in research developments

Molecular profiling has emerged as a key aspect of NET research, enabling the identification of specific biomarkers and genetic mutations associated with these tumors. These discoveries have led to the introduction of innovative treatment options such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). Moreover, the ongoing scientific discoveries contribute to a deeper understanding of molecular mechanisms and genetic factors, ultimately enhancing patient outcomes and expanding the range of available treatments, thereby driving market growth.

Threat:

Lack of awareness

Neuroendocrine tumors (NETs) are difficult to detect since they are comparatively uncommon and present with a variety of symptoms. These tumors may not be well known to many medical professionals, which could cause delayed or incorrect diagnoses. Additionally, lack of knowledge on NETs, causes them to incorrectly interpret symptoms and delay seeking medical attention. This lack of awareness also extends to the broader medical community, potentially leading to suboptimal management of NET cases.

COVID-19 Impact

The market for neuroendocrine tumor treatments was adversely affected by the COVID-19 pandemic. Patient outcomes were impacted by delayed neuroendocrine tumor detection and treatment as a result of lockdowns and restricted capacity in healthcare facilities. Clinical trials for innovative medicines were restricted, and the availability of healthcare services was stretched due to the reallocation of resources and attention toward addressing the pandemic. Furthermore, concerns about immunosuppression and financial limitations on healthcare systems also affected the willingness to start or maintain therapy, gradually hindering the market size.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is typically considered in cases where surgery and other treatments are less effective, often in the advanced or metastatic stages of NETs. Chemotherapy can help control symptoms, reduce tumor growth, and enhance the patient's quality of life, but treatment is not always curative. Moreover, targeted and individualized chemotherapy regimens are being investigated in order to reduce side effects and improve treatment outcomes for people with neuroendocrine tumors, which is boosting this segment's expansion.

The pancreatic neuroendocrine tumor segment is expected to have the highest CAGR during the forecast period

The pancreatic neuroendocrine tumor segment is anticipated to have the highest CAGR during the forecast period. These tumors arise from the endocrine cells of the pancreas, and their distinct characteristics necessitate specialized treatment considerations. Treatment approaches for pNETs involve a multidisciplinary strategy, considering factors such as tumor grade, stage, and functionality. Additionally, for advanced or metastatic pNETs, therapeutic options include somatostatin analogs, which help control hormone-related symptoms and inhibit pathways promoting tumor growth, which are driving this segment's growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to advanced diagnostic tools, such as PET-CT scans and molecular profiling that have enhanced the early detection and characterization of neuroendocrine tumors. Targeted therapies and immunotherapies have gained prominence, offering more effective and personalized treatment options. Furthermore, collaborative efforts among healthcare stakeholders, government bodies, and pharmaceutical companies are crucial to addressing these disparities and enhancing the overall NET treatment, which is driving this region's growth.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to government healthcare policies and insurance coverage that significantly influence patient access to these treatments. Key players such as Eli Lilly & Company, Novartis AG, Hutchison MediPharma Limited, and Pfizer Inc. are developing in a favorable environment due to the region's strict regulations and large public and private investments in healthcare and research. Regulatory bodies like the FDA (Food and Drug Administration) play a central role in drug and treatment device approvals, ensuring safety and efficacy, which are propelling this region's expansion.

Key players in the market:

Some of the key players in the Neuroendocrine Tumor Treatment Market include Novartis AG, Exelixis, Inc., Boehringer Ingelheim International GmbH, Tarveda Therapeutics, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer Inc., Ipsen Pharma, Progenics Pharmaceuticals, Inc., Eli Lilly & Company, Lantheus Holdings, Inc. and Jubilant Life Sciences Ltd.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In August 2023, Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines.

Therapies Covered:

Chemotherapy
Targeted Therapy
Somatostatin Analogues
Immunotherapy
Other Therapies

Disease Indications Covered:

Pancreatic Neuroendocrine Tumor
Lung Neuroendocrine Tumor
Gastrointestinal Neuroendocrine Tumor
Other Disease Indications

Route of Administrations Covered:

Parenteral
Oral

Site Analysis Covered:

Colon
Lungs
Small Intestine
Pancreas
Other Site Analysis

End Users Covered:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Neuroendocrine Tumor Treatment Market, By Therapy

5.1 Introduction
5.2 Chemotherapy
5.3 Targeted Therapy
5.4 Somatostatin Analogues
5.5 Immunotherapy
5.6 Other Therapies

6 Global Neuroendocrine Tumor Treatment Market, By Disease Indication

6.1 Introduction
6.2 Pancreatic Neuroendocrine Tumor
6.3 Lung Neuroendocrine Tumor
6.4 Gastrointestinal Neuroendocrine Tumor
6.5 Other Disease Indications

7 Global Neuroendocrine Tumor Treatment Market, By Route of Administration

7.1 Introduction
7.2 Parenteral
7.3 Oral

8 Global Neuroendocrine Tumor Treatment Market, By Site Analysis

8.1 Introduction
8.2 Colon
8.3 Lungs
8.4 Small Intestine
8.5 Pancreas
8.6 Other Site Analysis

9 Global Neuroendocrine Tumor Treatment Market, By End User

9.1 Introduction
9.2 Hospital Pharmacy
9.3 Online Pharmacy
9.4 Retail Pharmacy
9.5 Other End Users

10 Global Neuroendocrine Tumor Treatment Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Novartis AG
12.2 Exelixis, Inc.
12.3 Boehringer Ingelheim International GmbH
12.4 Tarveda Therapeutics
12.5 Dauntless Pharmaceuticals
12.6 Hutchison MediPharma Limited
12.7 AVEO Oncology
12.8 Pfizer Inc.
12.9 Ipsen Pharma
12.10 Progenics Pharmaceuticals, Inc.
12.11 Eli Lilly & Company
12.12 Lantheus Holdings, Inc.
12.13 Jubilant Life Sciences Ltd.

神経内分泌腫瘍治療市場の世界市場予測（～2030年）：治療法、病状、投与経路、部位分析、エンドユーザー、地域別の分析

Neuroendocrine Tumor Treatment Market Forecasts to 2030 - Global Analysis By Service, Animal Model, Model Type, End User and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の神経内分泌腫瘍治療市場：治療法別

第6章 世界の神経内分泌腫瘍治療市場：病状別

第7章 世界の神経内分泌腫瘍治療市場：投与経路別

第8章 世界の神経内分泌腫瘍治療市場：部位分析別

第9章 世界の神経内分泌腫瘍治療市場：エンドユーザー別

第10章 世界の神経内分泌腫瘍治療市場：地域別

第11章 主な発展

第12章 企業プロファイル